Tocofersolan
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Tocofersolan: From Vitamin E Deficiency to Amenorrhea
One-Sentence Summary
Tocofersolan (TPGS) is a water-soluble form of vitamin E, historically used to correct vitamin E deficiency in patients with chronic cholestasis. The TxGNN model predicts a possible link to Amenorrhea, but this prediction is currently supported by no clinical trials and no published literature — it is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Vitamin E deficiency associated with chronic cholestasis (based on known pharmacological use; not confirmed via regulatory label data) |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L5 |
| Norway Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, tocofersolan is a polyethylene glycol succinate ester of vitamin E (TPGS), used primarily as a micellar solubilizer to aid absorption of fat-soluble vitamin E in patients with impaired bile flow (e.g., cholestasis). Its established efficacy is limited to correcting vitamin E deficiency, not to any direct hormonal or reproductive pathway.
There is no known mechanistic pathway connecting vitamin E supplementation to hypothalamic-pituitary-ovarian axis regulation or menstrual cycle control. The high TxGNN score most likely reflects an indirect graph relationship — for example, shared nodes related to oxidative stress pathways — rather than a validated biological mechanism. Without supporting trial or literature evidence, this connection should be treated as exploratory only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Norway Market Information
Tocofersolan is not currently marketed in Norway (0 authorizations on record). No product license data is available for review.
Safety Considerations
Please refer to the package insert for safety information.
Additional Predicted Indication (Secondary Candidate)
A second candidate — Acne (TxGNN score: 99.03%, rank 9278) — was also flagged, with the same evidence profile: no clinical trials, no literature, and no direct pharmacological rationale beyond a theoretical antioxidant/anti-inflammatory link. This candidate carries the same L5 / Hold status and is not prioritized over amenorrhea.
Conclusion and Next Steps
Decision: Hold
Rationale: Both predicted indications rely solely on TxGNN model scores with no corroborating clinical trials, literature, or mechanistic pathway. Combined with the absence of MOA, safety, and regulatory data, there is currently no basis to advance either candidate beyond exploratory screening.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data from DrugBank or primary literature
- TFDA/regulatory label warnings and contraindications (currently a Blocking data gap)
- Preclinical or observational evidence linking vitamin E/TPGS to reproductive endocrine or dermatologic pathways
- DDI and safety profile data before any S1 safety pre-assessment can begin
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.